From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis.

From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis.

Item
http://www.wikidata.org/entity/Q38162082
Management of psoriasis patients with hepatitis B or hepatitis C virus infectionPsoriasis and comorbid diseases: Implications for management.Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab.Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses.Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014.The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature.The use of biologics in pregnant patients with rheumatic disease.Prevention of HBV reactivation in patients treated with biologic agents.Adalimumab use in patients with psoriasis and hepatitis B: a case series.Review of IL-17 inhibitors for psoriasis.Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?Liver Illness and Psoriatic Patients.Assessment and monitoring of biologic drug adverse events in patients with psoriasis.
P2860

From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis.

Item
http://www.wikidata.org/entity/Q38162082
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
From the Medical Board of the ...... ts in patients with psoriasis.
@en
type
label
From the Medical Board of the ...... ts in patients with psoriasis.
@en
prefLabel
From the Medical Board of the ...... ts in patients with psoriasis.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
From the Medical Board of the ...... ts in patients with psoriasis.
@en
P2093
P304
P31
P356
10.1016/J.JAAD.2013.08.049
P407
P433
P478
P577
P698